Bottom line
IXJ vs SWHFX: the short answer
IXJ (iShares Global Healthcare ETF) and SWHFX (Schwab Health Care Fund) share a meaningful slice of their top holdings — about 76% by weight.
IXJ is cheaper at 0.38% vs 0.8% — a difference of $42 a year per $10,000 invested.
Over five years, SWHFX returned +6.5% a year vs +6.4% for IXJ.
Updated Nov 19, 2026
IXJ vs SWHFX side by side
| IXJ | SWHFX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | iShares | Schwab |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.38% | 0.8% |
| Annual cost per $10k | $38 | $80 |
| 10-yr cost on $10k (prospectus) | $480 | $990 |
| Max front load | None | — |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +14.9% | +15.9% |
| 5-yr return (annualized) | +6.4% | +6.5% |
| 10-yr return (annualized) | +8.2% | +8.1% |
| Best quarter | +13.6% | +15.3% |
| Worst quarter | −11.8% | −12.1% |
| Net assets (fund) | $3.8B | $642.3M |
| Number of holdings | 124 | 80 |
| Portfolio turnover | 2% | 41% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | IXJ | SWHFX | Difference |
|---|---|---|---|
| 2025 | +14.9% | +15.9% | −1.1% |
| 2024 | +0.6% | +0.1% | +0.5% |
| 2023 | +3.5% | +0.7% | +2.8% |
| 2022 | −4.7% | −4.7% | −0.0% |
| 2021 | +19.5% | +23.3% | −3.8% |
| 2020 | +12.5% | +12.9% | −0.4% |
| 2019 | +23.4% | +17.6% | +5.7% |
| 2018 | +2.9% | +4.0% | −1.1% |
| 2017 | +20.3% | +20.2% | +0.1% |
| 2016 | −6.2% | −4.4% | −1.8% |
Source: Fund prospectus bar charts
Holdings overlap
18 of IXJ's top 25 holdings also appear in SWHFX's top 25.
| Holding | IXJ | SWHFX |
|---|---|---|
| Eli Lilly And Company | 10.93% | 13.92% |
| Johnson & Johnson | 7.04% | 6.94% |
| Abbvie Inc. | 5.12% | 5.81% |
| Unitedhealth Group Incorporated | 4.40% | 4.74% |
| Merck & Co., Inc. | 4.12% | 4.98% |
| Roche Holding AG | 3.75% | 2.29% |
| Novartis AG | 3.71% | 2.92% |
| Amgen Inc. | 2.54% | 2.58% |
| Thermo Fisher Scientific Incorporated | 2.42% | 2.16% |
| Abbott Laboratories | 2.05% | 1.60% |
| Gilead Sciences, Inc. | 2.04% | 3.24% |
| Vertex Pharmaceuticals Incorporated | 1.64% | 1.89% |
| Danaher Corporation | 1.56% | 1.47% |
| Bristol-myers Squibb Company | 1.53% | 2.44% |
| Stryker Corporation | 1.41% | 2.11% |
Source: SEC Form N-PORT
IXJ top 10
- Eli Lilly And Company — 10.93%
- Johnson & Johnson — 7.04%
- Abbvie Inc. — 5.12%
- Unitedhealth Group Incorporated — 4.40%
- Merck & Co., Inc. — 4.12%
- Astrazeneca Plc — 3.76%
- Roche Holding AG — 3.75%
- Novartis AG — 3.71%
- Amgen Inc. — 2.54%
- Thermo Fisher Scientific Incorporated — 2.42%
SWHFX top 10
- Eli Lilly & Co — 13.92%
- Johnson & Johnson — 6.94%
- AbbVie Inc — 5.81%
- Merck & Co Inc — 4.98%
- UnitedHealth Group Inc — 4.74%
- Gilead Sciences Inc — 3.24%
- Novartis AG — 2.92%
- Amgen Inc — 2.58%
- Bristol-Myers Squibb Co — 2.44%
- Medtronic PLC — 2.29%
FAQ
What is the difference between IXJ and SWHFX?
Which is cheaper, IXJ or SWHFX?
Should I own both IXJ and SWHFX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.